New Zealand

In New Zealand, the primary regulatory authority for health products is Medsafe, operating under the New Zealand Ministry of Health. The main governing legislation is the Medicines Act 1981, supplemented by the Medicines Regulations 1984, the Medical Devices (Conformity Assessment) Regulations 2020, and the Therapeutic Products Act 2023, which is progressively replacing the older framework. Medsafe is responsible for the pre-market evaluation and post-market surveillance of medicines, medical devices, diagnostics, and related therapeutic products. Pharmaceutical products require a formal product registration through a New Zealand Consent to Distribute (consent process), while medical devices are registered on the Web Assisted Notification of Devices (WAND) database, with risk-based requirements aligned to the Global Harmonization Task Force (GHTF) framework. Digital health tools and software as a medical device (SaMD) are increasingly assessed under guidance aligned with international frameworks, though specific dedicated legislation remains under development.

New Zealand accepts dossiers largely aligned with the Common Technical Document (CTD) format for pharmaceuticals, and applications may leverage prior approvals from comparable overseas regulators including the US FDA, European EMA, UK MHRA, Australian TGA, Health Canada, and the Swiss Swissmedic, under an expedited or abridged review pathway. Applicants are not required to have a local New Zealand entity as a prerequisite in all cases, but a New Zealand-based sponsor or agent is typically required to hold regulatory responsibility for the product. The landmark Therapeutic Products Act 2023, once fully implemented, will consolidate regulation of medicines, medical devices, natural health products, and related digital therapeutics under a single modernised framework, introducing updated conformity assessment requirements, a revised classification system, and strengthened post-market obligations. This reform represents the most significant regulatory restructuring in New Zealand in over four decades.

Public procurement of health products in New Zealand is primarily coordinated through Health New Zealand (Te Whatu Ora), the national health authority established following the health system reforms of 2022 which dissolved the former District Health Boards (DHBs). Health New Zealand operates as a single national commissioning and procurement entity, enabling more centralised and standardised tendering for pharmaceuticals, medical devices, diagnostics, and health services across the country. Pharmaceutical procurement is heavily shaped by PHARMAC (the Pharmaceutical Management Agency), a government agency responsible for managing a national formulary (the Pharmaceutical Schedule) and negotiating funding agreements for both community and hospital medicines and medical devices. PHARMAC conducts competitive tender processes and health technology assessments (HTAs), applying cost-utility analysis and budget impact modelling to determine which products receive government subsidy. Hospital medical devices and diagnostics may also be procured through national contracts managed by Health New Zealand, often leveraging aggregated national volume to achieve pricing leverage.

New Zealand does not rely on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income OECD member with a fully publicly funded domestic health procurement system. The private healthcare sector, including private hospitals and specialist clinics, procures products independently through commercial distribution channels and is not subject to PHARMAC funding decisions, though providers may reference the national schedule as a pricing benchmark. New Zealand does not operate formal local manufacturing preference policies in health procurement; however, Trans-Tasman arrangements with Australia mean that joint procurement initiatives and regulatory alignment with the Therapeutic Goods Administration (TGA) are common, providing a degree of bilateral market access facilitation. Suppliers entering the New Zealand market are generally expected to engage directly with PHARMAC for funding consideration alongside or following Medsafe registration.